Adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) and Nasu–Hakola disease: lesion staging and dynamic changes of axons and microglial subsets
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The brains of 10 Japanese patients with adult onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) encompassing hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS) and pigmentary orthochromatic leukodystrophy (POLD) and eight Japanese patients with Nasu–Hakola disease (N‐HD) and five age‐matched Japanese controls were examined neuropathologically with special reference to lesion staging and dynamic changes of microglial subsets. In both diseases, the pathognomonic neuropathological features included spherically swollen axons (spheroids and globules), axon loss and changes of microglia in the white matter. In ALSP, four lesion stages based on the degree of axon loss were discernible: Stage I, patchy axon loss in the cerebral white matter without atrophy; Stage II, large patchy areas of axon loss with slight atrophy of the cerebral white matter and slight dilatation of the lateral ventricles; Stage III, extensive axon loss in the cerebral white matter and dilatation of the lateral and third ventricles without remarkable axon loss in the brainstem and cerebellum; Stage IV, devastated cerebral white matter with marked dilatation of the ventricles and axon loss in the brainstem and/or cerebellum. Internal capsule and pontine base were relatively well preserved in the N‐HD, even at Stage IV, and the swollen axons were larger with a higher density in the ALSP. Microglial cells immunopositive for CD68, CD163 or CD204 were far more obvious in ALSP, than in N‐HD, and the shape and density of the cells changed in each stage. With progression of the stage, clinical symptoms became worse to apathetic state, and epilepsy was frequently observed in patients at Stages III and IV in both diseases. From these findings, it is concluded that (i) shape, density and subsets of microglia change dynamically along the passage of stages and (ii) increase of IBA‐1‐, CD68‐, CD163‐ and CD204‐immunopositive cells precedes loss of axons in ALSP.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglia-specific localisation of a novel calcium binding protein, Iba1
Ito, D., Imai, Y., Ohsawa, K., Nakajima, K., Fukuuchi, Y., & Kohsaka, S. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00040-0 · Cited by 1,476
Neuroinflammation in Parkinson's disease and its potential as therapeutic target
Wang, Q., Liu, Y., & Zhou, J. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0042-0 · Cited by 884
Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, M., Bird, T., Miranda, R., Salmaggi, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/342259 · Cited by 683 · cited 1×
“The causative genes are TREM2 (triggering receptor expressed on myeloid cells 2) and DNAX activating protein of 12 kDa (DAP12) (10, 40, 56, 61, 63).”
BackgroundBrites, D., & Fernandes, A. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00476 · Cited by 599 · cited 1×
“Microglial phenotype changes in ALSP and N-HD may be linked to depression and/or anxiety observed in patients with these diseases, as reported recently (11, 69).”
BackgroundThe role of inflammation and microglial activation in the pathophysiology of psychiatric disorders
Réus, G. Z., Fries, G. R., Stertz, L., Badawy, M., Passos, I. C., Barichello, T., Kapczinski, F., & Quevedo, J. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.018 · Cited by 594
Rademakers, R., Baker, M., Nicholson, A. M., Rutherford, N. J., Finch, N., Soto-Ortolaza, A., Lash, J., Wider, C., Wojtas, A., DeJesus-Hernandez, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.1027 · Cited by 571
Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts
Paloneva, J., Kestilä, M., Wu, J., Salminen, A., Böhling, T., Ruotsalainen, V., Hakola, P., Bakker, A. B. H., Phillips, J. H., Pekkarinen, P., et al. (2000) · Nature Genetics · doi:10.1038/77153 · Cited by 460 · cited 1×
“The causative genes are TREM2 (triggering receptor expressed on myeloid cells 2) and DNAX activating protein of 12 kDa (DAP12) (10, 40, 56, 61, 63).”
BackgroundCroisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-14 · Cited by 414
Jimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., & Vitorica, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3024-08.2008 · Cited by 383 · cited 1×
“In an AD mouse model, the APP 1 PS1 mouse, a distinctive shift from M2 to M1 activation in the brain has been observed (29).”
BackgroundIntracellular signaling in M‐CSF‐induced microglia activation: Role of Iba1
Imai, Y., & Kohsaka, S. (2002) · Glia · doi:10.1002/glia.10149 · Cited by 359
Identification of a microglia phenotype supportive of remyelination
Olah, M., Amor, S., Brouwer, N., Vinet, J., Eggen, B., Biber, K., & Boddeke, H. W. G. M. (2012) · Glia · doi:10.1002/glia.21266 · Cited by 358 · cited 1×
“MHCII-immunoreactive M1 cells are located at the edges of the lesions, which constitute the front line of the disease (68), or MHCII microgliaparticipate in remyelination (59).”
BackgroundDAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features
Paloneva, J., Mandelin, J., Kiialainen, A., Böhling, T., Prudlo, J., Hakola, P., Haltia, M., Konttinen, Y. T., & Peltonen, L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030027 · Cited by 318 · cited 1×
“CSF1R and TREM2/DAP12 are reportedly involved in microglial activation in the brain and bone marrow (2, 54, 62), and it has been shown that signal transduction of CSF1R and TREM2/DAP12 meets at the downstreams (47).”
BackgroundAhmed, Z., Shaw, G., Sharma, V. P., Yang, C., McGowan, E., & Dickson, D. W. (2007) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.6a7156.2007 · Cited by 258 · cited 2×
“IBA-1 calcium-binding protein microglial activation (1, 26)”
BackgroundNeumann, H., & Takahashi, K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.032 · Cited by 249
Peferoen, L. A. N., Vogel, D. Y. S., Ummenthum, K., Breur, M., Heijnen, P. D. A. M., Gerritsen, W. H., Peferoen-Baert, R. M. B., van der Valk, P., Dijkstra, C. D., & Amor, S. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000149 · Cited by 178 · cited 1×
“Microglia can switch between M1 and M2 phenotypic profiles in the MS lesions (64).”
BackgroundPey, P., Pearce, R. K., Kalaitzakis, M. E., Griffin, W. S. T., & Gentleman, S. M. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-21 · Cited by 128
CSF1R mutations in hereditary diffuse leukoencephalopathy with spheroids are loss of function
Pridans, C., Sauter, K. A., Baer, K., Kissel, H., & Hume, D. A. (2013) · Scientific Reports · doi:10.1038/srep03013 · Cited by 74 · cited 2×
“It had been reported that CSF1R gene mutations in cultured cells cause loss of signal transduction function (20, 66).”
Background
Cited by
van der Knaap, M. S., & Bugiani, M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1739-1 · Cited by 403
Oosterhof, N., Kuil, L. E., van der Linde, H. C., Burm, S. M., Berdowski, W., van Ijcken, W. F. J., van Swieten, J. C., Hol, E. M., Verheijen, M. H. G., & van Ham, T. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.113 · Cited by 178
“This is reminiscent of the increased microglia density we observed in deep brain regions of csf1ra / ;b haploinsufficient zebrafish (Oyanagi et al., 2017).”
BackgroundInfluentialPLD3 affects axonal spheroids and network defects in Alzheimer’s disease
Yuan, P., Zhang, M., Tong, L., Morse, T. M., McDougal, R. A., Ding, H., Chan, D., Cai, Y., & Grutzendler, J. (2022) · Nature · doi:10.1038/s41586-022-05491-6 · Cited by 155
Review: neuropathology of non-tau frontotemporal lobar degeneration
Neumann, M., & Mackenzie, I. R. A. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12526 · Cited by 144
White matter microglia heterogeneity in the CNS
Amor, S., McNamara, N. B., Gerrits, E., Marzin, M. C., Kooistra, S. M., Miron, V. E., & Nutma, E. (2022) · Acta Neuropathologica · doi:10.1007/s00401-021-02389-x · Cited by 89
Metadata
- Authors
- Oyanagi, K., Kinoshita, M., Suzuki‐Kouyama, E., Inoue, T., Nakahara, A., Tokiwai, M., Arai, N., Satoh, J., Aoki, N., Jinnai, K., Yazawa, I., Arai, K., Ishihara, K., Kawamura, M., Ishizawa, K., Hasegawa, K., Yagisita, S., Amano, N., Yoshida, K., Terada, S., Yoshida, M., Akiyama, H., Mitsuyama, Y., & Ikeda, S.
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2017-03-02
- Volume
- 27
- Issue
- 6
- Pages
- 748-769
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- OpenAlex
- W2519159792
- Cited by
- 53
- References
- 17
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.